EADV 2022: Risankizumab Effective in Long Term for Nail, Scalp, and Palmoplantar Psoriasis
Findings promising for 256 weeks of continuous treatment with a dose of 150 mg
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.